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Abstract: Primary immunodeficiency diseases (PID) are a heterogeneous group of disorders caused
by inborn errors of immunity, with affected children presenting with severe, recurrent or unusual
infections. Over 300 distinct genetic molecular abnormalities resulting in PID have been identified,
and this number continues to rise. Newborn screening for PID has been established in many countries,
with the majority of centers using a PCR-based T cell receptor excision circle (TREC) assay to screen
for severe combined immunodeficiency (SCID) and other forms of T cell lymphopenia. Multiplexed
screening including quantitation of kappa-recombining exclusion circles (KREC) has also been
described, offering advantages over TREC screening alone. Screening technologies are also expanding
to include protein-based assays to identify complement deficiencies and granulocyte disorders.
Given the rapid advances in genomic medicine, a potential future direction is the application of
next-generation sequencing (NGS) technologies to screen infants for a panel of genetic mutations,
which would enable identification of a wide range of diseases. However, several ethical and economic
issues must be considered before moving towards this screening strategy.
Keywords: newborn screening; primary immunodeficiency diseases; TREC; KREC; next-generation
sequencing
1. Introduction
Primary immunodeficiency diseases (PID) are a heterogeneous group of disorders which are
genetically determined inborn errors of immunity. In excess of 300 distinct genetic molecular
abnormalities resulting in PID have been identified, and this number continues to increase. Based
on estimates from the human connectome, more than 1000 genes interact with known PID genes [1].
Children with PID present with severe, recurrent or unusual infections, and these diseases are
associated with significant morbidity and mortality. Until recent years, there was no available testing
modality to identify these children prior to the onset of symptoms, frequently resulting in delayed
diagnosis and treatment, and a complicated clinical course. Currently available newborn screening
technologies have enabled the early identification of severe forms of PID, manifested by T and B
cell lymphopenia, which has been demonstrated to have a profound impact on patient outcomes [2].
PID were previously thought to represent rare disease entities, however through newborn screening
programs, true disease incidence rates can be determined and have proven to be higher than expected.
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Newborn screening for PID continues to be an evolving field, with the potential for future expansion
to include screening for other forms of PID such as granulocyte disorders and complement deficiency.
The future of newborn screening for the identification of PID and other inborn errors is likely to involve
a change in screening strategy, where next-generation sequencing will have an increasingly prominent
role, potentially even as up-front testing. Here, we review the past and present aspects of newborn
screening for primary immunodeficiency diseases, and discuss potential future directions.
2. The Past: Identification of Severe Combined Immunodeficiency as a Priority for
Newborn Screening
Since the initiation of population-based newborn screening using dried blood spots (DBS) in the
1960s using a method established by Guthrie and Susi [3], there have been significant advances in
our ability to screen asymptomatic infants for severe, life-threatening diseases for which treatment
is available, and where early diagnosis and treatment is essential for preventing serious sequelae.
For inclusion in population-based screening programs, diseases must meet a series of criteria as
described by Wilson and Jungner [4]. Severe combined immunodeficiency (SCID) is a life-threatening
condition resulting from a profound lymphocyte deficiency. It manifests with significant infections
and is uniformly fatal without treatment. SCID is curable with hematopoietic stem cell transplantation
(HSCT), and it has been demonstrated that outcomes are markedly improved for infants who are
diagnosed and undergo HSCT prior to the age of 3.5 months [2]. Diagnosis and treatment is frequently
delayed, and realistically, achieving this target is only possible if affected newborns are identified by
screening prior to the onset of symptoms, acquisition of infections and other complications. As such,
SCID meets the necessary criteria and is a suitable candidate for population-based newborn screening,
and this has been borne out in prospective screening trials [5,6].
3. The Present: Screening for T and B Cell Lymphopenia
A seminal paper was published by Chan and Puck in 2005, describing the T-cell receptor excision
circles (TREC) assay for the detection of SCID in a newborn screening setting [7]. TREC are small,
circular pieces of episomal DNA which are produced during T cell receptor (TCR) rearrangement in
naïve T cells, which serve as a surrogate marker of recent thymic emigrants. TREC copy numbers,
measurable by quantitative reverse transcription polymerase chain reaction (qRT-PCR), are markedly
reduced or absent in infants with SCID and other forms of T cell lymphopenia. Screening for SCID has
become part of routine newborn screening programs in all US states, the District of Columbia and the
Navajo Nation (Jeffrey Modell Foundation, http://www.info4pi.org). Several countries in Europe,
Australasia and the Middle East have also commenced SCID screening programs, or are evaluating
these in prospective studies (Table 1).
Table 1. Worldwide status of newborn screening programs for primary immunodeficiency diseases
(PID). TREC: T-cell receptor excision circles; KREC: kappa-recombining exclusion circles; ADA:
adenosine deaminase.
Country Screening Strategy Date of Commencement Reference




TREC 2008 (Wisconsin)National implementation






TREC/ADA 2010: Pilot study2010: Pilot study
2013: Pilot study
http://ipopi.org/
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Table 1. Cont.
Country Screening Strategy Date of Commencement Reference
Taiwan TREC 2010: Pilot study2012: National implementation Chien YH et al., 2017 [9]
Israel TREC 2011: Pilot study2015: National implementation Rechavi et al., 2017 [10]
The Netherlands TREC 2012: Pilot study2015: Application approved
Blom et al., 2017 [11]
http://ipopi.org/
Qatar TREC 2012: National implementation http://ipopi.org/
Germany TREC/KREC 2013: Pilot studyApplication in progress http://ipopi.org/
Sweden TREC/KREC 2013: Pilot study Barbaro et al., 2016 [6]
Japan TREC/KREC 2014: Pilot study http://ipopi.org/
France TREC 2014: Pilot study Audrain et al., 2014 [12]http://ipopi.org/
Spain
Andalucia TREC/KREC 2014: Pilot study
de Felipe et al., 2016 [13]
http://ipopi.org/
Norway TREC 2015: Pilot study http://ipopi.org/
Puerto Rico TREC 2016: National implementation Dorsey & Puck 2017 [8]http://www.info4pi.org/
















Brazil TREC Pilot study Kanegae et al., 2016 [14]
Denmark TREC Application in progressPilot study http://ipopi.org/
Iceland TREC/KREC Application in progressPilot study http://ipopi.org/
Iran TREC/KREC Pilot study Personal communication
Saudi Arabia TREC/KREC Pilot study http://ipopi.org/
Slovenia Pilot studyApplication in progress http://ipopi.org/
Turkey TREC/KREC Pilot study Personal communication
United Kingdom TREC Application in progressPilot study http://ipopi.org/
Australia Application in progress http://ipopi.org/







Czech Republic TREC/KREC Application in progress Personal communication
Poland Application in progress http://ipopi.org/
Portugal Application in progress http://ipopi.org/
Romania Application in progress http://ipopi.org/
Switzerland TREC/KREC Application in progress http://ipopi.org/
United Arab Emirates Applications in progress http://ipopi.org/
In addition to the detection of TREC levels as surrogate markers for thymic T cell output, it is
also possible to evaluate B cell production by quantifying kappa-recombining excision circles (KREC),
which are produced by similar mechanisms during rearrangement of the variable, diversity and joining
domains (V(D)J recombination) of the B cell immunoglobulin kappa gene [15]. A multiplexed assay
measuring TREC and KREC, along with beta-actin levels as a control for DNA quantity provides a
strategy for simultaneous screening for T and B cell lymphopenia [16].
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Screening for PID by measuring both TREC and KREC offers advantages over TREC screening
alone. This includes identification of patients with X-linked agammaglobulinemia (XLA), an antibody
deficiency disorder caused by mutations in the BTK gene which is essential for B cell development.
Consequently, there is an absence of B cells, lack of antibody production, and severe infections with
bacteria and other pathogens [17–19]. Mutations in other genes involved in B cell development have
also been described, giving rise to an XLA-like disease with a similar phenotype [20]. Both groups
of patients can be identified by low or absent KREC levels. Early identification of this disease is
important, as it facilitates timely commencement of gammaglobulin replacement therapy. In addition
to XLA, multiplexed TREC/KREC screening also facilitates diagnosis of individuals with late onset
adenosine deaminase (ADA) deficiency, some cases of Nijmegen breakage syndrome (NBS) and other
forms of PID which may otherwise be missed [16]. In the case of SCID, combined screening aids in
the diagnostic process and guides targeted molecular evaluation, as different mutations will give
rise to a variable pattern of T and B cell deficiency. Potential increased costs associated with KREC
screening in addition to TREC screening have been suggested as a disadvantage of combined screening.
Intrinsic costs of laboratory testing, patient follow-up and second tier testing must all be considered.
However, the additional costs of adding KREC quantitation to a TREC-only platform are negligible,
estimated to be less than €0.10 per test. Another proposed disadvantage of combined TREC/KREC
screening was a higher recall rate for abnormal KREC levels. However, results of our recent evaluation
of the combined TREC/KREC newborn screening program in Sweden show that the recall rate is
dependent upon cut off levels set, but the recall rate in our cohort was similar to that for TREC-only
testing programs [6], suggesting that this was unlikely to be an issue. There are some limitations of
TREC-based screening. Some cases of SCID will not be identified, in the case where T cells are present
but have abnormal function, or where the molecular defect lies downstream of TCR rearrangement
(including Zap70 Deficiency, major histocompatibility complex (MHC) class II deficiency and some
cases of delayed-onset adenosine deaminase (ADA) deficiency) [21–26].
4. The Future: Screening for Other Forms of PID
In addition to screening for immunodeficiency diseases that manifest with T and B cell
lymphopenia, expanded screening for the detection of other diseases such as complement deficiencies
and granulocyte disorders using protein-based assays has also been proposed. Disorders of
granulocyte number and function give rise to severe, recurrent bacterial and fungal infections,
and one possible method to identify these diseases involves measurement of granulocyte-specific
proteins. The complement system consists of a large number of interacting components. Individuals
with complement deficiency present variably, with significant bacterial infections caused by specific
pathogens, or severe autoimmune or renal disease. In these patients, complement protein levels are
reduced as a result of the underlying genetic mutation. It has been demonstrated that complement
proteins can be eluted from DBS samples, allowing identification of C2- and C3-deficient patients
at birth who have low or absent protein levels [27,28]. This can ultimately be expanded to
develop multiplexed assays which enable detection of multiple complement cascade components
and granulocyte specific proteins to enable detection of these disorders in the neonatal period, which
would enable early diagnosis and treatment, minimizing long-term complications in these patients.
Screening for granulocyte disorders and complement deficiency will be covered elsewhere in greater
detail in this special issue on newborn screening for PID.
Targeted genetic testing is another newborn screening approach, and this is currently employed
in screening algorithms for selected diseases such as cystic fibrosis [29]. Familial hemophagocytic
lymphohistiocytosis (FHL) is a primary immunodeficiency disorder manifesting with a life-threatening
inflammatory response secondary to impaired lymphocyte cytotoxicity. Several causative genetic
mutations have been identified [20]. In Scandinavia, 50% of FHL cases are due to homozygous
UNC13D inversion mutations, and a screening strategy based on the detection of reduced UNC13D
wild type gene copy numbers was demonstrated to be an effective method by which to identify affected
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individuals [30]. This approach could be expanded to enable identification of mutations in other FHL
genes, and may have a role in screening for other disorders.
5. The Future: The Role of Next-Generation Sequencing in Newborn Screening for PID
Since completion of sequencing of the human genome project in 2003, advances in next-generation
sequencing have progressed exponentially, resulting in an increased availability of testing, improved
bioinformatic pipelines for data analysis, a faster turn-around time and a decrease in associated costs.
This makes next-generation sequencing (NGS) an attractive and affordable modality to employ not
only in a diagnostic setting, but also as a potential screening tool. Given that there is no single or
multiplexed screening assay which can reliably detect all forms of PID at birth, we propose a screening
approach for PID where all newborns undergo whole genome sequencing (WGS), with rapid analysis
of the currently known 300+ genes, which would be expanded to include additional clinically relevant
genes as they are identified.
Current strategies for newborn screening include metabolic assays, TREC/KREC quantification
and targeted genetic studies, and this list is expected to expand. Second- and third-tier testing is
required to confirm the findings of the screening test, and to make a specific diagnosis. Targeted
mutation analysis or next-generation sequencing, including whole exome sequencing (WES) and
whole genome sequencing, is often required to determine the underlying molecular diagnosis. At the
Center for Metabolic Diseases (CMMS) at the Karolinska University Hospital in Stockholm, an aberrant
result on first-tier metabolic testing that cannot be rapidly confirmed with a second-line test is further
evaluated by genetic testing by WGS. This enables specific mutations to be identified in known
disease-causing genes. If no mutation is found, parents are counselled and consented to undergo
further genomic evaluation [31]. In this model, an aberrant test is followed up with WGS. As such,
the next logical step in screening methodology would be to screen newborns for a range of genetic
mutations using up-front NGS. With targeted sequencing being of limited value and the technical
limitations of WES, WGS seems the most appropriate choice.
Pavey et al. recently reported the results of WGS-based screening for PID in a cohort of
1349 newborn and parent trios, who were analyzed for variants in 329 known immunodeficiency
genes [32]. A genotype-first pipeline resulted in identification of 396 newborns with pathogenic/likely
pathogenic mutations, however on further analysis, only one individual was found to have a
genomically predicted immunodeficiency (complement component C9 deficiency). C9 deficiency
is associated with an increased risk of life-threatening Neisserial infection [20], and early institution
of prophylactic measures including immunization are of utmost importance in this patient group.
A phenotype-first pipeline was also applied, in which 29 infants were identified to have clinical features
suggestive of possible immunodeficiency, but did not have an identifiable mutation in any of the
interrogated PID genes. Three of these children had pathogenic mutations in other (non-PID) genes
which correlated clinically. No additional causative variants were found in the other children, the
majority of whom were considered to be unlikely to have a PID [32]. These findings are consistent
with results of a survey conducted by Boyle et al., who determined a PID prevalence of 1 in 1200
in the US [33]. Taken together, it is expected that screening 1000 newborns will identify one case of
PID, however utilizing a NGS approach enables identification of other disorders. This is the first
reported study evaluating genomic testing for PID as a first-line screening strategy in newborns.
Longer-term clinical follow-up in cohorts such as these, and larger studies are required to determine
test characteristics such as sensitivity and specificity.
The National Institutes of Health are currently undertaking the ‘Newborn Sequencing in Genomic
Medicine and Public Health’ (NSIGHT) project which will evaluate the role of up-front genomic testing
in neonates (https://www.genome.gov). These projects will include evaluation of exome sequencing
in newborn screening for currently screened and additional disorders, and investigate the role of rapid
turnaround genomic sequencing in the neonatal intensive care unit setting. They will also address
key ethical, legal and social implications of implementation of such programs. This will involve
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evaluating parental experiences related to receiving clinical information arising from genomic testing
in the newborn period, and medical practitioner experiences in terms of utilizing genomic information
and its impact upon clinical care delivery [34].
The notion of performing WGS on every infant at birth is controversial, and there are several
factors that need to be considered regarding this potential approach to screening. The Global
Alliance Paediatric Task Team recently published a series of recommendations regarding this screening
approach, highlighting clinical utility, management of incidental findings, cost-effectiveness, data
management, and ethical, legal and social implications as key areas for consideration [35].
5.1. Identification of Candidate Diseases and Genes to Be Evaluated in Newborn Genomic Screening Programs
The identification of key diseases for inclusion in genomic-based screening programs, selection
of appropriate gene candidates for interrogation, and establishment of a testing panel are major
considerations. In terms of screening for PID, an approach similar to that adopted by Pavey et al. [32]
involving interrogation of a gene panel inclusive of the currently-described 300+ PID genes is an
appropriate starting point. However, such panels would need to be regularly updated to include
newly identified genes. It is probable that patients without identifiable molecular causes for their
disease will have mutations in novel genes, and hence frequent revision of gene panels will enhance
our future diagnostic capabilities. Although we advocate for the use of WGS as a screening tool
for all newborns, this must proceed with caution. More than 8000 Mendelian diseases are currently
recognized (https://omim.org/), however, initial evaluation in a WGS-based newborn screening
program should only involve interrogation of genetic mutations which have a definite disease-causing
role and where a clear genotype/phenotype correlation exists. However, it is expected that over time,
there will be an increase in the number of screened genetic mutations and diseases.
In order to gain an appreciation of which disorders were likely to be significant causes of child
mortality, and hence, possible disease candidates for newborn screening, we evaluated the causes
of death in children less than 18 years of age in Sweden between 1987 and 2015 (Figure 1). There
were 19,957 deaths during this time period. Seventy-six deaths (0.38%) were attributable to a known
primary immunodeficiency disorder. Of these 76 cases, one death was attributed to common variable
immunodeficiency, 4 to PID with predominant antibody deficiency, 5 to PID in combination with
other major defects, 13 to combined immunodeficiency (including SCID), and 53 were attributed
to unspecified immunodeficiency diseases. In addition, 849 deaths (4.3%) were due to infectious
diseases and their complications, and it is likely that there were a considerable number of additional
cases of undiagnosed PID in this group. Tambe et al. evaluated causes of child and infant mortality
in the United Kingdom between 2006 and 2008, and found a mortality rate due to diseases of the
blood, blood-forming organs and the immune system of 1.8 per 1,000,000 children in the 5–15 year
age group [36], and 3.3 per 100,000 children aged less than 5 years [37]. Infectious diseases accounted
for 9.5 deaths per 1,000,000 in the 5–15 year age group [36], and 27.9 per 100,000 neonates and 36 per
100,000 children aged 28 days to 4 years [37]. There are some limitations of the studies performed by
our group and Tambe et al., given the degree of subjectivity in International Classification of Diseases
(ICD) code assignment and potential categorization of a disease in different groups, and some cases
might not be captured correctly due to a lack of detailed coding [23]. In addition, this type of analysis
does not capture the significant morbidity associated with survivorship of severe diseases such as
PID. Evaluation of such data facilitates identification of key diseases that result in death or significant
morbidity in infancy and childhood, which should therefore be prioritized as candidates for inclusion
in population-based newborn screening programs.
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5.3. Ethical, Legal and Social Implications
Population-based NGS screening raises several ethical, legal and social issues that must be
considered, and are not discussed here in detail. These considerations represent a key area which
will be addressed through the NSIGHT projects and similar studies evaluating newborn screening
using genomic testing. In many countries, newborn screening is offered as a standard of care, and
consent is typically obtained via an ‘opt out’ process. A change in approach to NGS screening would
lead to an added level of consent that needs to be obtained from families given the implications of
genetic testing. There is a risk that this could potentially deter families from engagement in screening
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programs. Genetic data storage and management, biobanking of genetic material and its implications
for other uses must also be considered. Variants of unknown significance are commonly found in
NGS analyses. A clear plan must be established for the identification and reporting of such results.
In addition, the finding of ‘unexpected’ or unrelated genetic mutations may have far-reaching effects
on the individual and their family. The potential for identification of mutations in genes known to
lead to debilitating or lifespan-reducing disease later in life for which no treatment exists must be
considered, and how this will be managed should also be considered.
5.4. A New Model for Newborn Screening
Population-based NGS screening strategies represent a reversed approach to current screening
practices, where typically a marker of disease is identified by a screening test, and then confirmed by
genetic analysis. It stands to be determined if an upfront NGS testing approach will ultimately save
time or money, given that functional tests may then be needed to confirm the genotype–phenotype
correlation. This also raises the question as to if NGS screening will ultimately replace current
screening tests, or if they would continue to be run in tandem. It is anticipated that the results of
prospective genomic-based newborn screening programs will answer many of these questions, and
inform future practice.
6. Conclusions
In the past, there was no method by which to identify infants with severe forms of PID, resulting
in delayed diagnosis and significant complications. At the present time, newborn screening for the
detection of severe forms of PID manifest by T and/or B cell lymphopenia using TREC or TREC/KREC
screening has been established in many countries. There is the potential for future expansion to
employ other screening modalities, such as protein-based assays and targeted genetic sequencing to
enable identification of other forms of PID. However, it is not currently possible to screen for a wide
range of diseases simultaneously using a single modality. It seems logical that the most effective and
efficient way to screen newborns for an extensive list of diseases, which differ in terms of classification,
pathophysiology and manifestation is using an up-front NGS testing strategy. Prior to adopting
a genomic screening approach, selection of appropriate gene candidates for inclusion in screening
panels, program structure, laboratory-clinical pipeline establishment, ethical, legal, social and financial
implications must be both considered and evaluated in large, prospective studies to inform decisions
regarding future implementation.
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